A protective role for GLUT1 is supported by the finding that peroxisome proliferator-activated receptor (PPAR) γ agonist rosiglitazone, shown to prevent kidney disease in a mouse model of T1DM (73) and to reduce albuminuria in patients with T2DM (74), increases glucose uptake into podocytes by enhancing membrane localization of GLUT1 (75). This evidence concerns the gene SLC2A1 and type 1 diabetes mellitus.